ARTELO BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $7.21M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 11, 2025 | After market close | – | – | – |
| Q1 FY2020 Ended Nov 30, 2019 | Jan 14, 2020 | Before market open | – | – | – |
| Q3 FY2019 Ended May 31, 2019 | Jul 15, 2019 | After market close | – | – | – |
Press releases
Announcements Artelo Biosciences filed with the SEC
Artelo Biosciences Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Artelo Biosciences Announces $11.0 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Artelo Biosciences Announces Closing of $11.0 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Artelo Biosciences Expands ART27.13 Development
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
INDEX TO AUDITED FINANCIAL STATEMENTS
Results of operations · Other events · EX-99.1 to Form 8-K
Artelo Biosciences Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Artelo Biosciences Announces Proposed Underwritten Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Artelo Biosciences Announces Proposed Underwritten Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
INDEX TO AUDITED FINANCIAL STATEMENTS
Results of operations · Other events · EX-99.1 to Form 8-K
Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024
Results of operations · Other events · EX-99.2 to Form 8-K
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Artelo Biosciences Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K